Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.
FDA chooses not to approve new nasal spray for heart rhythm issues
Etripamil's journey toward FDA approval hit a roadblock. The agency requested additional information on the drug, including a new facility inspection, in a response letter sent to Milestone Pharmaceuticals.

Dihydropyridines such as amlodipine have been the topic of some debate in recent months due to fears they lead to significant side effects.

Video of Kateita Hasanovic, RN, senior director, clinical EHR applications at Baptist Health, Jacksonville, Florida, explains how her large health system consolidated its Epic EHR and patient medication history.

How medication reconciliation data consolidation in the EHR enables better patient care

Baptist Health in Jacksonville, Florida, consolidated patient medication history from numerous facilities into one location in its Epic EHR to improve patient safety and allow data analytics.

Patisiran, marketed under the name Onpattro

FDA chooses not to approve patisiran for treating ATTR cardiomyopathy

The announcement came just weeks after an FDA subcommittee voted in favor of approval.

Merck is seeking FDA approval for sotatercept to be used as a treatment for pulmonary arterial hypertension

FDA grants speedy review to Merck's new drug for pulmonary arterial hypertension

The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.

Bivalirudin linked to key benefit over heparin for NSTEMI patients undergoing PCI

The two anticoagulants are associated with similar mortality rates. However, a new meta-analysis in Circulation may have cardiologists favoring bivalirudin over heparin.

artificial intelligence robot evaluates healthcare data

Novo Nordisk spends $60M on advanced AI in search of new cardiovascular medications

Novo Nordisk is working with Valo Health to identify potential new treatments for cardiometabolic conditions. If it proves to be a fruitful collaboration, the initial payment of $60 million will be just the beginning.

Warfarin after TAVR is safe, but fails to boost outcomes

Researchers examined two-year data from transfemoral TAVR patients treated with low-dose aspirin and 30 days of warfarin or just aspirin on its own.

FDA approves empagliflozin for treating chronic kidney disease

The popular SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, has already been approved by the FDA to treat type 2 diabetes and heart failure.

Pharmaceutics

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes

FDA chooses not to approve new nasal spray for heart rhythm issues